Exp Clin Endocrinol Diabetes 2013; 121(07): 436-439
DOI: 10.1055/s-0033-1345124
Article
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

C332C Genotype of Glyoxalase 1 and its Association with Late Diabetic Complications

Glo1 Genotype and Diabetic Neuropathy

Authors

  • J. B. Groener

    1   Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
  • P. Reismann

    1   Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
  • T. Fleming

    1   Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
  • H. Kalscheuer

    1   Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
  • D. Lehnhoff

    1   Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
  • A. Hamann

    1   Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
  • P. Roser

    1   Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
  • A. Bierhaus

    †   Deceased
  • P. P. Nawroth

    1   Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
  • G. Rudofsky

    1   Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
Further Information

Publication History

received 08 January 2013
first decision 08 March 2013

accepted 15 April 2013

Publication Date:
17 June 2013 (online)

Preview

Abstract

Aims/Introduction:

Glyoxalase 1 catalyses the detoxification of methylglyoxal, a major precursor of advanced glycation end products associated with aging, neurodegenerative diseases, and microvascular complications of diabetes. Here, we examine a possible association of a single nucleotide polymorphism of glyoxalase 1 gene (Glo1 A332C, rs4746 or rs2736654) with the prevalence of microvascular diabetic complications in patients with type 1 and type 2 diabetes.

Materials and Methods:

Genotyping was performed in 209 patients with type 1 and 524 patients with type 2 diabetes using polymerase chain reaction and subsequent cleavage by restriction endonuclease Bsa I.

Results:

Frequencies of the glyoxalase 1 genotypes were different with respect to diabetes type with a significantly higher prevalence of A332A-genotype in type 1 diabetes (35.9% vs. 27.3%; p=0.03). In type 1 diabetes, there was no correlation of any genotype with diabetic retinopathy, nephropathy or neuropathy. In contrast, type 2 diabetic patients homozygous for the C332C allele showed a significantly increased prevalence of diabetic neuropathy (p=0.03; OR=1.49 [95%-CI: 1.04; 2.11]), while no association with diabetic nephropathy or retinopathy was found. However, the significance of this association was lost after correction for multiple testing.

Conclusions:

Our data suggest a possible association of C332C-genotype of the glyoxalase 1 gene with diabetic neuropathy in type 2 diabetes, supporting the hypothesis that methylglyoxal might be an important mediator of diabetic neuropathy in type 2 diabetes.